We believe in making sure every family has access to rare disease medicines and the care they need. No matter where a patient lives or the regulatory governance of that country, we can safely launch and efficiently deliver vital medication and clinical services for families that need it most.
As your partner, we offer a bespoke, fully managed service designed to meet the specific challenges of launching and delivering orphan drugs for rare diseases to patients in Europe and beyond. We provide the clinical expertise to improve patient adherence and persistence while ensuring patient safety at all times and deliver a complete solution across the drug lifecycle.
EXPLORE OUR 5 STEP PROCESS
We make sure clinical trials are conducted safely from start to finish, supporting you with everything from nursing and clinical care, testing and monitoring solutions and data collection. We have supported 27 clinical trials over a number of years, 10 in rare disease areas.
We have over 28 years of experience supporting pharma companies with pre- and post-approval patient access programs. As your partner, we can provide a proven supply chain, clinical support and data collection, as well as support you with your Individual Funding Request (IFR) and getting local advanced budget notification.
We offer a fully managed service that’s designed to meet the specific challenges of launching and supplying orphan drugs for ultra-rare diseases to patients in Europe. These solutions are tried and tested, as bespoke as your needs, and fully EMA GDP compliant for pre- and post-launch, including cold chain management and track and trace.
We seamlessly manage the entire patient and clinical support pathway with the patient at the very heart of everything we do. We co-ordinate with local hospitals and clinicians and have multi-clinical interventions for patients and families at home or clinic to support adherence and persistence.
We have European coverage in the home or in clinical setting for outcome monitoring and controlled data collation. That includes pharmacovigilance reporting, patient safety follow ups, and real-world evidence for extensions, reimbursement approval, and contribution to registries.
